awmsg logo



everolimus (Afinitor®)


Reference No. 142

Publication date:
13/08/2012


Appraisal information

everolimus (Afinitor®) tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 12/06/2012
AWMSG meeting date: 18/07/2012
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2112
Ministerial ratification: 07/08/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Everolimus (Afinitor®) is recommended as an option for use within NHS Wales for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download